Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru


ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Атмосфера. Новости кардиологии
2022 / N 1

Подходы к терапии пациентов с артериальной гипертонией и сопутствующей бронхолегочной патологией (хроническая обструктивная болезнь легких, бронхиальная астма)
Т.В. Адашева, Е.И. Саморукова, С.С. Долбин, В.В. Ли, В.С. Задионченко, Н.В. Высоцкая

References

1. Revol B, Jullian-Desayes I, Tamisier R, Joyeux-Faure M. Case 2. In: Cardiovascular complications of respiratory disorders. ERS monograph. Martínez-García MA, Pépin JL, Cazzola M, editors. Sheffield, England: European Respiratory Society; 2020: 305-13.
2. Russian Scientific Medical Society of Therapists. Clinical recommendations. Diagnosis and treatment of patients with chronic obstructive pulmonary disease and arterial hypertension. Therapy 2019;5(Suppl):1-57 (In Russian).
3. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement DL, Coca A, de Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Ruilope L, Zanchetti A, Kerins M, Kjeldsen SE, Kreutz R, Laurent S, Lip GYH, McManus R, Narkiewicz K, Ruschitzka F, Schmieder RE, Shlyakhto E, Tsioufis C, Aboyans V, Desormais I; ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal 2018 Sep;39(33):3021-104.
4. Morales DR, Jackson C, Lipworth BJ, Donnan PT, Guthrie B. Adverse respiratory effect of acute β-blocker exposure in asthma: a systematic review and meta-analysis of randomized controlled trials. Chest 2014 Apr;145(4):779-86.
5. Loth DW, Brusselle GG, Lahousse L, Hofman A, Leufkens HG, Stricker BH. @β-adrenoceptor blockers and pulmonary function in the general population: the Rotterdam study. British Journal of Clinical Pharmacology 2014 Jan;77(1):190-200.
6. British Thoracic Society; Healthcare Improvement Scotland. SIGN158. British guideline on the management of asthma. Available from: www.brit-thoracic.org.uk/quality-improvement/guidelines/asthma/ Accessed 2022 Jul 08.
7. Short PM, Williamson PA, Anderson WJ, Lipworth BJ. Randomized placebo-controlled trial to evaluate chronic dosing effects of propranolol in asthma. American Journal of Respiratory and Critical Care Medicine 2013 Jun;187(12):1308-14.
8. Tiotiu A, Novakova P, Kowal K, Emelyanov A, Chong-Neto H, Novakova S, Labor M. Beta-blockers in asthma: myth and reality. Expert Review of Respiratory Medicine 2019 Sep;13(9):815-22.
9. Baker JG, Wilcox RG. β-blockers, heart disease and COPD: current controversies and uncertainties. Thorax 2017 Mar;72(3):271-6.
10. Ekström MP, Hermansson AB, Ström KE. Effects of cardiovascular drugs on mortality in severe chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine 2013 Apr;187(7):715-20.
11. Su TH, Chang SH, Kuo CF, Liu PH, Chan YL. β-blockers after acute myocardial infarction in patients with chronic obstructive pulmonary disease: a nationwide population-based observational study. PLoS One 2019 Mar;14(3):e0213187.
12. Nielsen AO, Pedersen L, Sode BF, Dahl M. β-blocker therapy and risk of chronic obstructive pulmonary disease – a Danish nationwide study of 1.3 million individuals. EClinicalMedicine 2019 Jan;7:21-6.
13. Liao KM, Lin TY, Huang YB, Cuo CC, Chen CY. The evaluation of β-adrenoceptor blocking agents in patients with COPD and congestive heart failure: a nationwide study. International Journal of Chronic Obstructive Pulmonary Disease 2017 Aug;12:2573-81.
14. Puente-Maestu L, Álvarez-Sala LA, de Miguel-Díez J. β-blockers in patients with chronic obstructive disease and coexistent cardiac illnesses. COPD Research and Practice 2015 Nov;1:11.
15. Bhatt SP, Wells JM, Kinney GL, Washko GR Jr, Budoff M, Kim YI, Bailey WC, Nath H, Hokanson JE, Silverman EK, Crapo J, Dransfield MT; COPDGene Investigators.. β-blockers are associated with a reduction in COPD exacerbations. Thorax 2016 Jan;71(1):8-14.
16. Dransfield MT, Voelker H, Bhatt SP, Brenner K, Casaburi R, Come CE, Cooper JAD, Criner GJ, Curtis JL, Han MK, Hatipoğlu U, Helgeson ES, Jain VV, Kalhan R, Kaminsky D, Kaner R, Kunisaki KM, Lambert AA, Lammi MR, Lindberg S, Make BJ, Martinez FJ, McEvoy C, Panos RJ, Reed RM, Scanlon PD, Sciurba FC, Smith A, Sriram PS, Stringer WW, Weingarten JA, Wells JM, Westfall E, Lazarus SC, Connett JE; BLOCK COPD Trial Group. Metoprolol for the prevention of acute exacerbations of COPD. The New England Journal of Medicine 2019 Dec;381(12):2304-14.
17. Cazzola M, Calzetta L, Rinaldi B, Page C, Rosano G, Rogliani P, Matera MG. Management of chronic obstructive pulmonary disease in patients with cardiovascular diseases. Drugs 2017 May;77(7):721-32.
18. Lin R, Peng H, Nguyen LP, Dudekula NB, Shardonofsky F, Knoll BJ, Parra S, Bond RA. Changes in β2-adrenoceptor and other signaling proteins produced by chronic administration of ‘β-blockers’ in a murine asthma model. Pulmonary Pharmacology and Therapeutics 2008;21(1):115-24.
19. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2020 report. Available from: https://goldcopd.org/gold-reports/ Accessed 2022 Jul 08.
20. Tan WSD, Liao W, Zhou S, Mei D, Wong WS. Targeting the renin-angiotensin system as novel therapeutic strategy for pulmonary diseases. Current Opinion in Pharmacology 2018 Jun;40:9-17.
21. Kilburg-Basnyat BJ, Selgrade MK, Gowdy KM. Chemical- and drug-induced asthma. Comprehensive Toxicology 2018;11(5):623-37.
22. Christiansen SC, Schatz M, Yang SJ, Ngor E, Chen W, Zuraw BL. Hypertension and asthma: a comorbid relationship. The Journal of Allergy and Clinical Immunology. In Practice 2016 Jan-Feb;4(1):76-81.
23. Myou S, Fujimura M, Kamio Y, Ishiura Y, Kurashima K, Tachibana H, Hirose T, Hashimoto T. Effect of losartan, a type 1 angiotensin II receptor antagonist, on bronchial hyperresponsiveness to methacholine in patients with bronchial asthma. American Journal of Respiratory and Critical Care Medicine 2000 Jul;162(1):40-4.
24. Christiansen SC, Zuraw BL. Treatment of hypertension in patients with asthma. The New England Journal of Medicine 2019 Sep;381(11):1046-57.
25. Rabe KF, Hurst JR, Suissa S. Cardiovascular disease and COPD: dangerous liaisons? European Respiratory Review 2018 Oct;27(149):180057.
26. Petersen H, Sood A, Meek PM, Shen X, Cheng Y, Belinsky SA, Owen CA, Washko G, Pinto-Plata V, Kelly E, Celli B, Tesfaigzi Y. Rapid lung function decline in smokers is a risk factor for COPD and is attenuated by angiotensin-converting enzyme inhibitor use. Chest 2014 Apr;145(4):695-703.
27. Parikh MA, Aaron CP, Hoffman EA, Schwartz JE, Madrigano J, Austin JHM, Kalhan R, Lovasi G, Watson K, Stukovsky KH, Barr RG. Angiotensin-converting inhibitors and angiotensin II receptor blockers and longitudinal change in percent emphysema on computed tomography. The multi-ethnic study of atherosclerosis lung study. Annals of the American Thoracic Society 2017 May;14(5):649-58.
28. Di Marco F, Guazzi M, Vicenzi M, Santus P, Cazzola M, Pappalettera M, Castellotti P, Centanni S. Effect of enalapril on exercise cardiopulmonary performance in chronic obstructive pulmonary disease: a pilot study. Pulmonary Pharmacology & Therapeutics 2010 Jun;23(3):159-64.
29. Paulin P, Maritano Furcada J, Ungaro CM, Bendelman G, Waisman GD, Castro HM, Giunta DH, Ferreyro BL. Effect of angiotensin 2 receptor blockers on chronic obstructive lung disease mortality: a retrospective cohort study. Pulmonary Pharmacology & Therapeutics 2017 Jun;44:78-82.
30. Kim J, Lee JK, Heo EY, Chung HS, Kim DK. The association of renin-angiotensin system blockades and pneumonia requiring admission in patients with COPD. International Journal of Chronic Obstructive Pulmonary Disease 2016 Sep;11:2159-66.
31. Lai CC, Wang YH, Wang CY, Wang HC, Yu CJ, Chen L. Comparative effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on the risk of pneumonia and severe exacerbations in patients with COPD. International Journal of Chronic Obstructive Pulmonary Disease 2018 Mar;13:867-74.
32. Bratel T, Hedenstierna G, Nyquist O, Ripe E. The use of a vasodilator, felodipine, as an adjuvant to long-term oxygen treatment in COLD patients. The European Respiratory Journal 1990 Jan;3(1):46-54.
33. Saadjian AY, Philip-Joet FF, Vestri R, Arnaud AG. Long-term treatment of chronic obstructive lung disease by nifedipine: an 18-month haemodynamic study. European Respiratory Journal 1988 Aug;1(8):716-20.
34. Dart RA, Gollub S, Lazar J, Nair C, Schroeder D, Woolf SH. Treatment of systemic hypertension in patients with pulmonary disease: COPD and asthma. Chest 2003 Jan;123(1):222-43.
35. Cazzola M, Noschese P, D’Amato G, Matera MG. The pharmacologic treatment of uncomplicated arterial hypertension in patients with airway dysfunction. Chest 2002 Jan;121(1):230-41.
36. Karoli NA, Rebrov AP, Roshchina AA, Sergeyeva VA, Arkhangelskaya EE. Efficacy and safety of amlodipine maleate in patients with chronic obstructive pulmonary disease and bronchial asthma with concomitant arterial hypertension. Rational Pharmacotherapy in Cardiology 2010;6(2):173-8 (In Russian).
37. Adasheva TV, Zadionchenko VS, Demicheva OYu, Bagatyrova KM. Calcium antagonists – proven effects and clinical benefits. Medical Council 2009;2:53-9 (In Russian).
38. Twiss MA, Harman E, Chesrown S, Hendeles L. Efficacy of calcium channel blockers as maintenance therapy for asthma. British Journal of Clinical Pharmacology 2002 Mar;53(3):243-9.
39. Chiu KY, Li JG, Lin Y. Calcium channel blockers for lung function improvement in asthma: a systematic review and meta-analysis. Annals of Allergy, Asthma & Immunology 2017 Dec;119(6):518-23.e3.
40. Adasheva TV, Zadionchenko VS, Pavlov SV, Fedorova IV, Matsiyevich MV, Poryvkina ON, Li VV, Mironova MA. Organoprotective and pleiotropic effects of amlodipine in patients with hypertension and chronic obstructive pulmonary disease. Heart: Journal for Practicing Physicians 2010;9(3):165-71 (In Russian).
41. Flamenbaum W. Diuretic use in the elderly: potential for diuretic-induced hypokalemia. The American Journal of Cardiology 1986 Jan;57(2):38A-43A.
42. Lipworth BJ, McDevitt DG, Struthers AD. Prior treatment with diuretic augments the hypokalemic and electrocardiographic effects of inhaled albuterol. The American Journal of Medicine 1989 Jun;86(6 Pt 1):653-7.
43. Rutten FH, Cramer MJ, Lammers JW, Grobbee DE, Hoes AW. Heart failure and chronic obstructive pulmonary disease: an ignored combination? European Journal of Heart Failure 2006 Nov;8(7):706-11.
44. Krane NK, Wallin JD. Managing the elderly patient with both hypertension and pulmonary disease. Geriatrics 1987 Apr;42(4):45-52.
45. Vozoris NT, Wang X, Austin PC, O’Donnell DE, Aaron SD, To TM, Gershon AS. Incident diuretic drug use and adverse respiratory events among older adults with chronic obstructive pulmonary disease. British Journal of Clinical Pharmacology 2018 Mar;84(3):579-89.
46. Herrin MA, Feemster LC, Crothers K, Uman JE, Bryson CL, Au DH. Combination antihypertensive therapy among patients with COPD. Chest 2013 May;143(5):1312-20.
47. DiNicolantonio JJ. Hydrochlorothiazide: is it a wise choice? Expert Opinion on Pharmacotherapy 2012 Apr;13(6):807-14.
48. Madkour H, Gadallah M, Riveline B, Plante GE, Massry SG. Indapamide is superior to thiazide in the preservation of renal function in patients with renal insufficiency and systemic hypertension. The American Journal of Cardiology 1996 Feb;77(6):23B-5B.
49. Bataillard A, Schiavi P, Sassard J. Pharmacological properties of indapamide. Clinical Pharmacokinetics 1999;37(Suppl 1):7-12.
50. Astashkin EI, Glezer MG, Petrov EA, Sokolova IN. Indapamide effects on free oxygen radicals produced by blood phagocytes in patients with heart failure. Russian Journal of Cardiology 2012;17(4):43-7 (In Russian).
51. Bhalla KK. Evaluation of the effect of indapamide on moderate benign essential hypertension complicated by airways obstruction. Postgraduate Medical Journal 1981;57(Suppl 2):34-6.
52. Ovcharenko SI, Morozova TE, Nersesyan ZN. Chronic obstructive pulmonary disease concurrent with hypertension: evaluation of the therapeutic effect of prolonged-release indapamide. Therapeutic Archive 2015;87(8):44-50 (In Russian).
  

[ Содержание выпуска N 1 | Выпуски журнала | Список журналов ]